🔎 Trials Near Me

Akèy › Limfòm selil B

Etid klinik pou Limfòm selil B ap rekrite nan Etazini

67 etid pou Limfòm selil B ap rekrite patisipan nan sit atravè Etazini.

Vil ki gen plis etid

Pa eta

Etid ki fèk mete ajou

Tèks ofisyèl etid la (Anglè)

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07439653

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06350318

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT05615636

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

Ap rekriteFaz 1/2
31 Days – 30 Years · Tout sèks · Mizajou Sep 14, 2026 · NCT04544592

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06526793

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT05272384

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06564038

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06393738

Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma

Ap rekriteEtid obsèvasyon
Laj 4 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07652580

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 31, 2026 · NCT07516093

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07520006

A Study of ARC-02 in B-cell NHL

Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT07691606

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Aug 25, 2026 · NCT05389423

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT05826535

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT07220616

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT04792502

Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.